We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
-5.72%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$322M
AUM Growth
-$34.8M
Cap. Flow
-$3.33M
Cap. Flow %
-1.03%
Top 10 Hldgs %
62.73%
Holding
76
New
14
Increased
20
Reduced
18
Closed
19

Top Buys

Rank Stock Value
1
ENSG icon
The Ensign Group
ENSG
+$14.9M
2
GSK icon
GSK
GSK
+$11.9M
3
ASND icon
Ascendis Pharma A/S
ASND
+$11.2M
4
NVST icon
Envista
NVST
+$8.88M
5
DXCM icon
DexCom
DXCM
+$6.92M

Top Sells

Rank Stock Value
1
RCM
R1 RCM Inc. Common Stock
RCM
+$23.3M
2
EHTH icon
eHealth
EHTH
+$12.3M
3
RDUS
Radius Health, Inc.
RDUS
+$8.96M
4
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$8.38M
5
NUVA
NuVasive, Inc.
NUVA
+$5.37M

Sector Composition

Rank Sector Weight
1 Healthcare 90.47%
2 Real Estate 4.59%
3 Industrials 2.01%
4 Communication Services 1.04%
5 Miscellaneous 1%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BDSI
26
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$2.98M 0.92%
708,020
+351,746
+99% +$1.5M
ARQL
27
DELISTED
Arqule Inc
ARQL
$2.96M 0.92%
412,388
-39,300
-9% -$369K
HSKA
28
DELISTED
Heska Corp
HSKA
$2.89M 0.9%
40,824
+5,900
+17% +$443K
EHTH icon
29
eHealth
EHTH
$38.4M
$2.85M 0.88%
42,653
-136,086
-76% -$12.3M
AMRN
30
CALL
Amarin Corp
AMRN
$295M
$2.44M 0.76%
+8,055
New +$2.81M
CYH icon
31
Community Health Systems
CYH
$413M
$2.19M 0.68%
+607,383
New +$1.58M
FATE icon
32
Fate Therapeutics
FATE
$291M
$2.18M 0.68%
140,656
-77,200
-35% -$1.48M
CYTK icon
33
Cytokinetics
CYTK
$10B
$2.07M 0.64%
+181,700
New +$2.28M
TCDA
34
DELISTED
Tricida, Inc. Common Stock
TCDA
$2.02M 0.63%
65,568
-22,000
-25% -$737K
MGNX icon
35
MacroGenics
MGNX
$263M
$1.98M 0.61%
154,824
-35,799
-19% -$516K
XENE icon
36
Xenon Pharmaceuticals
XENE
$5.81B
$1.94M 0.6%
215,609
-8,731
-4% -$82.6K
APLS
37
DELISTED
Apellis Pharmaceuticals
APLS
$1.92M 0.59%
79,509
-37,800
-32% -$1.04M
BCRX icon
38
BioCryst Pharmaceuticals
BCRX
$2.51B
$1.88M 0.58%
654,460
+312,000
+91% +$970K
COLL icon
39
Collegium Pharmaceutical
COLL
$786M
$1.84M 0.57%
160,295
+19,295
+14% +$220K
SCPH
40
DELISTED
scPharmaceuticals
SCPH
$1.3M 0.4%
221,636
+47,339
+27% +$267K
AGRX
41
DELISTED
Agile Therapeutics
AGRX
$1.08M 0.33%
+455
New +$1.12M
IVC
42
DELISTED
Invacare Corporation
IVC
$970K 0.3%
129,361
-80,922
-38% -$454K
AFMD
43
DELISTED
Affimed
AFMD
$947K 0.29%
32,217
– –
OTIC
44
DELISTED
Otonomy, Inc.
OTIC
$899K 0.28%
376,342
+181,913
+94% +$433K
CDXS icon
45
Codexis
CDXS
$174M
$864K 0.27%
+63,000
New +$991K
SVRA icon
46
Savara
SVRA
$1.08B
$839K 0.26%
316,679
+74,536
+31% +$186K
DCPH
47
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$747K 0.23%
22,000
-283,233
-93% -$8.38M
OPTN
48
DELISTED
OptiNose
OPTN
$736K 0.23%
7,007
– –
EIGR
49
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$715K 0.22%
2,324
– –
DRNA
50
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$590K 0.18%
41,074
– –
1
2
3 4

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
GIA
Guyasuta Investment Advisors Pittsburgh, Pennsylvania $1.94B AUM 32.92% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

Eversept Partners's Q3 2019 Portfolio in Review

As of Q3 2019, Eversept Partners held 76 positions worth $322M, down 9.7% from $357M the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Eversept Partners's Q3 2019 filing shows 14 new, 20 increased, 18 reduced and 19 closed positions. Its largest new stake was Envista: 318,000 shares worth $8.87M. The largest sale was R1 RCM Inc. Common Stock, an estimated $23.3M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 82% a quarter earlier, followed by Real Estate and Industrials.

  • Eversept Partners's largest Q3 2019 buy was Envista: 318,000 shares worth $8.87M.
  • Eversept Partners added most to The Ensign Group in Q3 2019, an estimated $14.9M increase.
  • Eversept Partners's biggest Q3 2019 reduction was R1 RCM Inc. Common Stock, cutting an estimated $23.3M.
  • Eversept Partners fully exited NuVasive, Inc. in Q3 2019, selling an estimated $5.37M.
  • Eversept Partners's ten largest holdings make up 63% of its $322M portfolio in Q3 2019.
  • Eversept Partners opened 14 new positions and closed 19 in Q3 2019.
  • Eversept Partners's portfolio value fell 9.7% quarter-over-quarter to $322M.

Based on Eversept Partners's 13F filing for Q3 2019, filed 13 Nov 2019.